The initial results of the long-awaited BEST-CLI (Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia) trial were recently published in the New England Journal of Medicine. There is a lack of prospective, randomized data to guide treatment of peripheral arterial disease, and this landmark trial is worthy of review and analysis by any practitioner treating CLTI.
Commentary on "A Novel Temporary Stent For Treatment of Infrapopliteal Arteries in Conjunction With Drug-Coated Balloon Angioplasty: The DEEPER Pilot Study" by Mustapha, et al.
Commentary on Khan A, Green DL, Santilli S, et al. Preoperative C-reactive protein levels predict readmission following elective vascular surgery. J Crit Limb Ischemia. 2022;2(2):E39-E44.
Commentary on Jammeh ML, Suggs J, Adams GL, et al. Outcomes of orbital atherectomy in patients with critical limb threatening ischemia and diabetes. J Crit Limb Isch. 2022;2(2):E29-E37. Epub 2022 Apr 12.
Board Certified Plastic Surgeon Earl M. Johnson, Jr, comments on a study by Fujihara et al, who evaluate the current impact of plastic surgeons in managing wounds for patients with CLTI.
Dr Zeller comments on a recent JCLI meta-analysis by Al Halabi et al, who examined paclitaxel-coated drug-coated balloon (DCB) angioplasty in infrapopliteal artery lesions and found significant benefits for the use of DCB.
The recently published JCLI study by Perlander and colleagues offers an opportunity to focus on the existing gaps in our understanding of cost-effectiveness in the care for CLTI patients.
Editorial commentary on Pietzsch et al's "Cost-Effectiveness of Percutaneous Deep Vein Arterialization for Patients With No-Option Chronic Limb-Threatening Ischemia: An Exploratory Analysis Based on the PROMISE I Study."
An editorial commentary on Ghare et al's "Outcomes among patients with chronic critical limb ischemia with no revascularization option: systematic review and meta-analysis."
Editorial commentary on Mustapha et al's "Chronic total occlusions: association between characteristics and long-term outcomes in critical limb ischemia."
While CLI is becoming increasingly prevalent and deadly, CLI awareness and data are still severely lacking. The journal focus will be to harness quality data and clinical advances and to disseminate this information in a timely manner to all clinicians involved in the treatment of this complex and debilitating disease.